Alvotech and Advanz Pharma have announced EC marketing authorisations for Gobivaz, a biosimilar to Simponi, across the EEA.

“As the first biosimilar to Simponi (golimumab) to gain approval in the European market, we are committed to expanding access ...

The approvals cover Gobivaz 50 mg/0.5 mL and 100 mg/mL in pre-filled syringes and autoinjectors, for treating adults with ...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...

Alvotech & Advanz Pharma receive marketing approval across the EEA for Gobivaz, a first-in-market biosimilar to Simponi: Reykjavik, Iceland Saturday, November 22, 2025, 14:00 Hrs ...

Icelandic biosimilars company Alvotech and privately-held UK firm Advanz Pharma today announced that the European Commission ...

The buying on the counter came after the company received the approval for listing its equity shares on the Capital Market ...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and ...

Nonartricular pain — particularly widespread NAP — was linked to worse physical, emotional, and social well-being among adults with early RA.

Cedars-Sinai investigators may have figured out why certain immunosuppressive treatments don't work well in rheumatoid ...

Rheumatoid arthritis begins years before pain ever appears, and scientists have now mapped the hidden immune battle that ...